TICKERNERD
Menu
XBIOXBIOHealthcare · Biotechnology

XBIO Stock Forecast: Xenetic Biosciences, Inc. Price Predictions for 2026-2027

Last close, 30 Oct 2026
$2.05
−3.30% on the day

Ticker Nerd's systematic factor model, run across ~4,600 US stocks, ranks it 31 of 100 as at 31 Oct 2026 — in the lower half.

Market cap
$4.8M
Ticker Nerd rank
31/ 100
Median analyst target
—
Analysts covering
1
Revenue$661K+12.0% y/y
Operating income−$972K
Net income−$930K
Free cash flow−$875K
Quarterly, 8 quarters to 30 June 2026 · latest quarter's figure shown
Total return, dividends reinvested
1W
+19.2%
1M
−11.6%
YTD
−5.5%
1Y
−37.7%
From 52W high
−56.1%
From 52W low
+19.2%
$1.72
$4.67
52-week range, adjusted closes · the dot is the last close
Ticker Nerd rank

XBIO stock analysis: one number for the whole business

Consensus tells you what everyone already believes. The model scores Xenetic Biosciences, Inc. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.

Where the model ranks itAs at 31 Oct 2026
31/ 100

Percentile across ~4,600 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested

Size
95
Volatility
79
Growth
61
Momentum
44
Quality
40
Issuance
34
Accruals
28
Revisions
25
Value
12

Size (95): Smaller than most of the companies we track.

Value (12): The shares cost a lot relative to the profits and assets behind them.

Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.

Wall Street

XBIO stock forecast 2026-2027: analyst price targets & predictions

The bullish and bearish analyst opinions on XBIO, reported as data — targets and ratings, the market's view beside the model's.

Share price and the analyst range, 12 monthsAdjusted close, US dollars
$2.00$2.50$3.00$3.50$4.00Jan 26Apr 26Jul 26Oct 26XBIO

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Data provided by Twelve Data

What Wall Street says1 analysts
0 Buy1 Hold0 Sell
Recent analyst actionsNewest first
DateFirmActionRatingTarget
9 Apr 2025HC Wainwright & Co.ReiteratesNeutral—
20 Mar 2025HC Wainwright & Co.ReiteratesNeutral—
5 Dec 2024HC Wainwright & Co.ReiteratesNeutral—
22 Nov 2024HC Wainwright & Co.ReiteratesNeutral—
20 Aug 2024HC Wainwright & Co.ReiteratesNeutral—
16 May 2023HC Wainwright & Co.DowngradeNeutral—
11 Apr 2023HC Wainwright & Co.ReiteratesBuy$4.00
2 May 2022HC Wainwright & Co.MaintainsBuy$5.00 → $4.00
11 Jan 2021HC Wainwright & Co.MaintainsBuy$2.00 → $5.00
25 Nov 2020Ladenburg ThalmannInitiatesBuy—
20 Dec 2016Ladenburg ThalmannInitiatesBuy—

Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.

Market Radar

This page is one stock. Monday covers all of them.

XBIO appears in the Radar on the weeks it earns a place.

  • Market Radar, every Monday: the week's biggest rank moves across ~4,600 US stocks, and the reason for each.
  • The AI build-out map, free: every AI company we track, part by part, and one part in full with each verdict.

Free. Unsubscribe any time.

The AI build-out map
PDF

  • AI cloud capacity

    MSFTAMZNGOOGLORCL

  • AI chips

    NVDAAVGOAMDMU

  • AI networking and serversIn full

    ANETDELLLITECRDO

  • Data centre power

    VRTCEGGEVVST

Performance

XBIO vs the S&P 500

Both lines are total return — dividends reinvested — so the comparison is honest on both sides.

Over the twelve months to 30 Oct 2026, Xenetic Biosciences, Inc. returned −37.7% against +12.4% for the S&P 500, dividends included.

XBIO vs S&P 500, last 12 monthsTotal return, rebased to 100
6080100120140Jan 26Apr 26Jul 26Oct 26XBIOS&P 500

Download this chart as an image — free to reuse; link this page as the source.

Data provided by Twelve Data

Estimates

XBIO analyst estimate revisions

Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.

Which way the estimates are movingThis fiscal year
Analysts raising
0
Analysts cutting
0
Fundamentals

Xenetic Biosciences, Inc. (XBIO) financial data

A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.

Valuation
Trailing P/E
−1.3×

Cheaper than 84% of US stocks

Price / sales
1.5×

Cheaper than 58% of US stocks

Price / book
0.8×

Cheaper than 75% of US stocks

EV / EBITDA
0.6×

Cheaper than 59% of US stocks

Growth & margins
Revenue growth (YoY)
12.0%

Higher than 57% of US stocks

Earnings growth (YoY)
12.0%

Higher than 51% of US stocks

Gross margin
—
Operating margin
−147.1%

Higher than 12% of US stocks

Net margin
−75.9%

Higher than 8% of US stocks

Returns & dividend
Return on equity
−47.0%

Higher than 22% of US stocks

Return on assets
−26.8%

Higher than 16% of US stocks

Dividend yield
0.0%

Higher than 1% of US dividend payers

Bars mark the percentile across the ~4,600 US stocks Ticker Nerd covers, among those reporting the figure.

Key statistics

Xenetic Biosciences, Inc. (XBIO) statistics: revenue, profit & scale

The headline figures, each with its date. Every row carries its own link — cite it straight from here.

  • Xenetic Biosciences, Inc. has a market value of $4.8M and an enterprise value of −$1.7M.

  • Revenue in the twelve months to 30 June 2026: $3.3M. The latest quarter grew 12.0% year on year.

  • Net income over the same four quarters: −$2.5M, a −75.9% net margin.

  • Free cash flow in the twelve months to 30 June 2026: −$2.3M.

  • Shares outstanding: 2.3M.

  • Trailing P/E: −1.3×; forward P/E: −3.1× — the forward figure prices analyst consensus estimates, not reported earnings.

  • Forward dividend yield: 0.00%, paying out 0% of earnings.

  • Xenetic Biosciences, Inc. employs 2 people — $1.6M of revenue per employee.

Statement figures: company filings via Twelve Data, four quarters to 30 June 2026 · market figures as at 1 Nov 2026

Data provided by Twelve Data

Peers

XBIO vs competitors

The nearest names by industry and size, scored by the same model — like for like.

Its peer group, ranked by the same modelBiotechnology
CompanyMarket capTKN rank
XBIOXenetic Biosciences, Inc.$4.8M31
CDIOCardio Diagnostics Holdings, Inc.$4.9M20
AZTRAzitra, Inc.$4.7M42
IMNNImunon, Inc.$5.1M23
PULMPulmatrix, Inc.$5.1M48
SNTISenti Biosciences Holdings, Inc.$5.1M42
TRAWTraws Pharma, Inc.$4.5M48

Look up any of the roughly 4,600 stocks we score.

The rank is the raw material. Whether the rules would actually own Xenetic Biosciences, Inc. — and when they’d sell — is the membership. See the Ticker Nerd 20 →

News

Latest XBIO news & analysis

Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma

Accesswire · 15 Oct 2026positive

Xenetic said its partner PeriNess reported that the first patient was dosed in an investigator-initiated study at Tel Aviv Sourasky University Medical Center. The study evaluates systemic recombinant human DNase with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma; initial efficacy data are expected in Q2 2027.

Why it matters — The study marks the first clinical evaluation of Xenetic’s systemic DNase technology as an adjunct to CAR T-cell therapy.

Xenetic Biosciences, Inc. (XBIO) M&A Call Prepared Remarks Transcript

Seeking Alpha · 16 Sept 2026neutral

Seeking Alpha published the prepared remarks transcript from Xenetic Biosciences, Inc.'s (XBIO) merger and acquisition call. The item presents the company's prepared statements from the M&A call without additional commentary or analysis.

Why it matters — XBIO watchers would look to this transcript for the company's own statements regarding its M&A activity, providing direct insight into the deal as communicated by management.

Micro Cap Xenetic Biosciences Expands Therapeutic Platform With Santersus Acquisition

Benzinga · 16 Sept 2026positive

Xenetic Biosciences entered into a definitive share exchange agreement to acquire Santersus AG, a privately held therapeutic medical device company advancing a selective blood purification platform. The move expands Xenetic's therapeutic platform through the acquisition.

Why it matters — XBIO watchers would care because the acquisition expands the company's therapeutic platform through a new selective blood purification technology.

Xenetic Biosciences and Santersus AG Announce Definitive Share Exchange Agreement to Create Global Leader in NET-Targeting Therapeutics

Accesswire · 16 Sept 2026positive

Xenetic Biosciences announced a definitive share exchange agreement to acquire all outstanding shares of Santersus AG in an all-stock transaction, creating a Nasdaq-listed clinical-stage company focused on NET-targeting therapeutics. The combined company, expected to trade as Santersus Bio, Inc. under ticker SNTS, will combine Santersus' NucleoCapture blood purification platform with Xenetic's DNase technology.

Why it matters — For Xenetic shareholders, this transaction significantly transforms the company into a multi-indication clinical-stage business with four first-in-class NET-targeting programs, including pivotal-stage sepsis and SLE programs that have received FDA Breakthrough Device Designation.

Xenetic Biosciences Reports Second Quarter 2026 Financial Results and Highlights Strengthened Scientific Foundation Supporting Continued Advancement of Proprietary DNase Platform

Accesswire · 7 Aug 2026positive

Xenetic Biosciences reported its second quarter 2026 financial results and provided a corporate update on the advancement of its proprietary DNase platform, highlighting positive preclinical data presented at the ASCO Annual Meeting and expanded collaborative research initiatives.

Why it matters — XBIO watchers would care because the company is generating translational data and pursuing non-dilutive funding through royalties to support its core DNase platform development, which could strengthen the scientific case for future clinical trials.

FAQ

Frequently asked questions about XBIO stock

Is XBIO stock a buy right now?

Of the 1 analysts covering Xenetic Biosciences, Inc., 0 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Xenetic Biosciences, Inc. 31 out of 100 across roughly 4,600 US stocks as at 31 Oct 2026. None of this is personal advice — it does not consider your circumstances.

How does Ticker Nerd's model rank XBIO?

As at 31 Oct 2026, Xenetic Biosciences, Inc. ranks 31 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,600 US stocks, built from its factor families. Its strongest factor family is Size (95 of 100).

What is the XBIO stock forecast for 2030?

No analyst covering Xenetic Biosciences, Inc. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for XBIO are extrapolating price history, which says nothing about the business.

How has XBIO stock performed over the past year?

Xenetic Biosciences, Inc. returned -37.7% over the 12 months to 30 Oct 2026, with dividends reinvested. Past performance does not indicate future returns.

What does Xenetic Biosciences, Inc. do?

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers.

What is the latest news on XBIO?

The most recent item we track (Accesswire, 15 Oct 2026): "Xenetic Biosciences and PeriNess Announce First Patient Dosed in Investigator-Initiated Study at Tel Aviv Sourasky University Medical Center Evaluating Systemic DNase in Combination with CAR T Cells for Large B-Cell Lymphoma". Xenetic said its partner PeriNess reported that the first patient was dosed in an investigator-initiated study at Tel Aviv Sourasky University Medical Center. The study evaluates systemic recombinant human DNase with anti-CD19 CAR T-cell therapy in patients with large B-cell lymphoma; initial efficacy data are expected in Q2 2027.

Company

About Xenetic Biosciences, Inc.

Xenetic Biosciences, Inc. is a biopharmaceutical company focused on developing immune-oncology technologies for hard-to-treat cancers. The company’s current work centers on its DNase platform, which is designed to target neutrophil extracellular traps (NETs) and support the effectiveness of existing cancer treatments such as immunotherapies. Xenetic Biosciences is also advancing product candidates including XBIO-015 and XBIO-020 for pancreatic carcinoma and other solid tumors, along with platform technologies such as PolyXen and XCart. In addition to oncology, the company has programs that address related therapeutic areas, including anemia in chronic kidney disease through ErepoXen. Headquartered in Framingham, Massachusetts, Xenetic Biosciences serves as a specialized biotechnology player with a pipeline oriented toward novel treatment approaches across oncology and selected adjacent indications.

CEO Mr. James F. Parslow · 2 employees · United States · https://www.xeneticbio.com